ASLN Company Profile and Key Details

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) closed at $0.60 USD, losing -$0.10 (-14.27%) from the previous close of $0.70. The stock is currently mid-range between its 52-week high and low $0.47 and $17.04. With a market capitalization of about $777.12 million, ASLAN Pharmaceuticals Limited is classified as a small-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 102.49 thousand shares, trading with heavier-than-usual volume. Headquartered in Singapore, None, ASLAN Pharmaceuticals Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carl Alan Jason Morton Firth EMBA,, the company employs approximately 35 people and listed since May 04, 2018. ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.

Short-term trend indicators are bullishly aligned (SMA20 -71.05%, SMA50 -79.16%, SMA200 -88.33%). The stock’s 14-day RSI is 21.7 (weak momentum), while the ATR of 0.37 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.64% below its high and over 26.32% above its low.

ASLAN Pharmaceuticals Limited has 2.83 million shares outstanding. The public float is 410.33 million shares, elevated short interest at 1.46% of float. This equals 38.32 thousand shares. The short ratio is 1.85 days. Institutional investors hold 3916.0% of the float. Insiders own 8.0%.

ASLAN Pharmaceuticals Limited generated EPS of -$15.94 over the past year. Five-year average earnings growth is 17.51%. The latest quarter delivered EPS of -$0.88. The next quarter is forecast at $nan. Next year's EPS is expected at -$34.99. ASLAN Pharmaceuticals Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 09, 2024, missed forecasts by -76.84%. The prior quarter beat by 89.71%. Over the last six quarters, Apple has recorded several small beats. These include 48.57% in April 05, 2024.

ASLAN Pharmaceuticals Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that ASLAN Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -56.67%, with price expected at $0.26 by August 28, 2024, within a range of $0.00 to $1.10 3-Month Outlook: Projected fall of -76.67%, reaching $0.14 by November 12, 2024, with a range of $0.00 to $1.23. 1-Year Outlook: Projected loss of -76.67%, with price at $0.14 by August 14, 2025, within a range of $0.00 to $0.89.

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares are up 14.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ASLAN Pharmaceuticals Limited trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.15, suggesting 1925.0% upside. Our AI forecast model points to short-term weakness (-56.67% over two weeks), a medium-term fall (-76.67% over three months), and a longer-term loss (-76.67% over one year), with expected trading ranges indicating moderate volatility.

ASLAN Pharmaceuticals Limited trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 64.76 and a price-to-book ratio of -0.19 indicating negative book value, which may reflect financial stress. The P/FCF stands at -16.76, also above market averages.